¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°£ÇÐȸ APASL 2022 (DAY 1) : 2022-03-30

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑ°£ÇÐȸ APASL 2022 (DAY 1) : 2022-03-30
±³À°ÀÏÀÚ : 2022-03-30
±³À°Àå¼Ò : (¿Â, ¿ÀÇÁ¶óÀÎ º´Çà) ¿ÀÇÁ¶óÀÎ Àå¼Ò: ¼­¿ï ÄÚ¿¢½º  
±³À°ÁÖÁ¦ : (¿Â-¿ÀÇÁº´Çà) APASL 2022 (DAY 1)
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : APASL 2022 Áغñ»ç¹«±¹
¿¬¶ôó : 02-707-0091  
À̸ÞÀÏ : apasl2022@insession.co.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 15 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 800,000¿ø      
ºñ°í Category Early Bird Rate Regular Rate Onsite Rate December 31(Fri), 2021 February 20(Sun), 2022 Off-line Virtual Off-line Virtual Off-line VirtualAPASL Member USD 300 USD200 USD400 USD300 USD 500 USD 400Non APASL Member USD 500 USD 300 USD 600 USD 400 USD 700 USD 500Trainee/Resident/Nurse USD 200 USD 100 USD 300 USD 200 USD 400 USD 300Accompanying Person USD 150 - USD 200 - USD 300 -Industry Partner USD 600 USD 600 USD 700 USD 700 USD 800 USD 800 / *»çÀüµî·Ï2022³â 2¿ù 20ÀÏ(ÀÏ)±îÁö [ÇöÀå] Àü¹®ÀÇ 30¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 15¸¸¿ø, µ¿¹ÝÀÚ 15¸¸¿ø, Industry Partner 70¸¸¿ø [¿Â¶óÀÎ] Àü¹®ÀÇ 25¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 12¸¸¿ø, Industry Partner 70¸¸¿ø, *ÇöÀåµî·Ï [ÇöÀå] Àü¹®ÀÇ 35¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 18¸¸¿ø, µ¿¹ÝÀÚ 18¸¸¿ø, Industry Partner 80¸¸¿ø [¿Â¶óÀÎ] Àü¹®ÀÇ 30¸¸¿ø, ÀüÀÓÀÇ/Àü°øÀÇ/°£È£»ç 15¸¸¿ø, Industry Partner 80¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-30 101, 1F 10:30~10:50 Introduction to single-cell RNA sequencing (including nuclear RNA-sequecing)  Jong-Eun Park(Korea Advanced Institute of Science and Technology) 
±³À°½Ã°£ 03-30 101, 1F 10:50~11:20 Study of the human liver cell atlas  Thomas Baumert(INSERM, University of Strasbourg) 
±³À°½Ã°£ 03-30 101, 1F 11:20~11:50 Single-cell RNA sequencing in HCC  Zemin Zhang(School of Life Sciences, Peking University) 
Åä·Ð 03-30 101, 1F 11:50~12:00 Discussion  () 
±³À°½Ã°£ 03-30 101, 1F 13:30~13:50 Overview of the liver immune system  Eui-Cheol Shin(Korea Advanced Institute of Science and Technology) 
±³À°½Ã°£ 03-30 101, 1F 13:50~14:10 Characteristics of liver NK cells  Cliona O(School of Medicine, Trinity Biomedical Science Institute, Trinity College Dublin) 
±³À°½Ã°£ 03-30 101, 1F 14:10~14:30 T cell responses against HBV  Masanori Isogawa(Research Center for Drug and Vaccine Development, NIID) 
±³À°½Ã°£ 03-30 101, 1F 14:30~14:50 T-cell engineering for the treatment of liver diseases  Antonio Bertoletti(Duke-NUS Medical School) 
Åä·Ð 03-30 101, 1F 14:50~15:00 Discussion  () 
±³À°½Ã°£ 03-30 101, 1F 15:30~15:50 Update in HBV research  Peter Revill(Royal Melbourne Hospital) 
±³À°½Ã°£ 03-30 101, 1F 15:50~16:10 Recent progress in HBV entry  Koichi Watashi(National Institute of Infectious Diseases) 
±³À°½Ã°£ 03-30 101, 1F 16:10~16:30 Development of capsid inhibitors  Sung-Gyoo Park(College of Pharmacy Seoul National University) 
±³À°½Ã°£ 03-30 101, 1F 16:30~16:50 HBV integration and HCC  Shiou-Hwei Yeh(National Taiwan University Hospital) 
Åä·Ð 03-30 101, 1F 16:50~17:00 Discussion  () 
±³À°½Ã°£ 03-30 102, 1F 10:30~10:50 Emerging role of artificial intelligence and big data in liver diseases  Wai-Kay Seto(The University of Hong Kong) 
±³À°½Ã°£ 03-30 102, 1F 10:50~11:10 Clinical research with big data in hepatology: promises and challenges  Terry Cheuk-Fung Yip(Faculty of Medicine, The Chinese University of Hong Kong) 
±³À°½Ã°£ 03-30 102, 1F 11:10~11:30 Deep learning using electronic medical records in liver diseases  Tung-Hung Su(National Taiwan University Hospital) 
±³À°½Ã°£ 03-30 102, 1F 11:30~11:50 Machine-learning approach for novel predictive models  Ryosuke Tateishi(Graduate School of Medicine, The University of Tokyo) 
Åä·Ð 03-30 102, 1F 11:50~12:00 Discussion  () 
±³À°½Ã°£ 03-30 102, 1F 13:30~13:50 Human genome and liver diseases  Masashi Mizokami(National Center for Global Health and Medicine) 
±³À°½Ã°£ 03-30 102, 1F 13:50~14:10 Genetic and genomic methods to study risk of HBV and HCV infection and patient outcome  Hwai-I Yang(Genomic Research Center, Academia Sinica) 
±³À°½Ã°£ 03-30 102, 1F 14:10~14:30 Continuous molecular spectrum of liver cancers associated with radio-genomic and histologic features  Hyun Goo Woo(Ajou University School of Medicine) 
±³À°½Ã°£ 03-30 102, 1F 14:30~14:50 How to translate genomic understandings into clinical practice  Jean-Charles Nault(Jean Verdier Hospital) 
Åä·Ð 03-30 102, 1F 14:50~15:00 Discussion  () 
±³À°½Ã°£ 03-30 102, 1F 15:30~15:50 How to write a good paper?  Seung Up Kim(Yonsei University College of Medicine) 
±³À°½Ã°£ 03-30 102, 1F 15:50~16:10 Tips for selecting right journal for submission  Jia-Horng Kao(National Taiwan University College of Medicine) 
±³À°½Ã°£ 03-30 102, 1F 16:10~16:30 Tips for impressing the editor  Jean-Charles Nault(Jean Verdier Hospital) 
±³À°½Ã°£ 03-30 102, 1F 16:30~16:50 Reasons why some papers are accepted or rejected?  Paolo Angeli(University-Teaching Hospital of Padova) 
Åä·Ð 03-30 102, 1F 16:50~17:00 Discussion  () 
±³À°½Ã°£ 03-30 201+202+203, 2F 09:00~09:20 APASL 2022 PG course: Future trends in hepatology  Jeong Won Jang(College of Medicine, The Catholic University of Korea) 
±³À°½Ã°£ 03-30 201+202+203, 2F 09:20~09:40 Personalized treatment of viral hepatitis  Teerha Piratvisuth(Songklanagarind Hospital, Prince of Songkla University) 
±³À°½Ã°£ 03-30 201+202+203, 2F 09:40~10:00 Genetics and epigenetics in non-alcoholic fatty liver disease  Won Kim(Seoul National University College of Medicine) 
±³À°½Ã°£ 03-30 201+202+203, 2F 10:00~10:20 Translating omics data into biomarker discovery for liver cancer  Irene O. L. Ng(The University of Hong Kong) 
Åä·Ð 03-30 201+202+203, 2F 10:20~10:30 Discussion  () 
±³À°½Ã°£ 03-30 201+202+203, 2F 10:30~10:50 NAFLD versus lean NAFLD or MAFLD  Vincent Wong(Faculty of Medicine, The Chinese University of Hong Kong) 
±³À°½Ã°£ 03-30 201+202+203, 2F 10:50~11:10 Targeting the gut-liver-brain connection  Jasmohan S. Bajaj(Virginia Commonwealth University School of Medicine) 
±³À°½Ã°£ 03-30 201+202+203, 2F 11:10~11:30 Innovative strategies for a cure of hepatitis B  Seng Gee Lim(National University Health System) 
±³À°½Ã°£ 03-30 201+202+203, 2F 11:30~11:50 Immuno-oncology in liver cancer: A change of paradigm  Maria Reig(Hospital Clinic, University of Barcelona) 
Åä·Ð 03-30 201+202+203, 2F 11:50~12:00 Discussion  () 
±³À°½Ã°£ 03-30 201+202+203, 2F 13:30~13:50 New therapeutic targets in AIH, PBC, and PSC  Atsushi Tanaka(Teikyo University School of Medicine) 
±³À°½Ã°£ 03-30 201+202+203, 2F 13:50~14:10 Intestinal immune-microbiome interactions in alcoholic hepatitis  Ki Tae Suk(Hallym University College of Medicine) 
±³À°½Ã°£ 03-30 201+202+203, 2F 14:10~14:30 Immuno-microenvironment in NASH-associated HCC  Amany Zekry(St George Hospital) 
±³À°½Ã°£ 03-30 201+202+203, 2F 14:30~14:50 Immune tolerance and rejection in liver transplantation  Jong Young Choi(College of Medicine, The Catholic University of Korea) 
Åä·Ð 03-30 201+202+203, 2F 14:50~15:00 Discussion  () 
±³À°½Ã°£ 03-30 201+202+203, 2F 15:30~15:50 Coagulopathy in cirrhosis: Balancing between bleeding and thrombotic state  Ashok Choudhury(Institute of Liver and Biliary Sciences) 
±³À°½Ã°£ 03-30 201+202+203, 2F 15:50~16:10 Pulmonary complications of cirrhosis  Diana A Payawal(Fatima University Medical Center) 
±³À°½Ã°£ 03-30 201+202+203, 2F 16:10~16:30 Beta adrenergic blockade in cirrhosis: Do good or harm?  Dao Viet Hang(Hanoi Medical University) 
±³À°½Ã°£ 03-30 201+202+203, 2F 16:30~16:50 Managing acute-on-chronic liver failure to successful recovery or transplant  Rajiv Jalan(University College London Medical School, Royal Free Hospital) 
Åä·Ð 03-30 201+202+203, 2F 16:50~17:00 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°£ÇÐȸ APASL 2022 (DAY 1) : 2022-03-30""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ°£ÇÐȸ APASL 2022 (DAY 2) : 2022-03-31
´ÙÀ½±Û 2022³â ´ëÇÑÀÓ»óÅëÇÕÀÇÇÐȸ Çмú´ëȸ : 2022-03-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
489 Àü³² Á¦257Â÷ ´ëÇѳ»°úÇÐȸ ±¤ÁÖÀü³²Áöȸ Çмú´ëȸ : 2018-09-06 0 573 2018-08-22
488 °æ³² ´ëÇÑÇǺΰúÇÐȸ º£Ã¼Æ®º´ÀÇ ÃÖ½ÅÁö°ß¿¡ °üÇÏ¿© : 2018-09-06 0 654 2018-08-22
487 Ãæ³² °Ç¾ç´ëÇб³º´¿ø ´ëÇÑÇǺΰúÇÐȸ ÃæûÁöºÎÇÐȸ : 2018-09-06 0 855 2018-08-22
486 ´ë±¸ °è¸í´ëÇб³ µ¿»êÀÇ·á¿ø ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ Á¦234Â÷ °æºÏÁöȸ Áý´ãȸ : 2018-09-06 0 729 2018-08-22
485 °æ±â °¡Å縯´ëÇб³ ºÎõ¼º¸ðº´¿ø ´ëÇѺñ´¢±â°úÇÐȸ 2018 Á¦ 3Â÷ ÀÎõ.°æ±âÁöȸ Áý´ãȸ : 2018-09-06 2 1,448 2018-08-22
484 °æ³² ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018³âµµ 3Â÷ ºÎ»ê¿ï»ê°æ³² ÈäºÎ¿Ü°ú Áý´ãȸ ¹× °­¿¬ : 2018-09-06 0 686 2018-08-22
483 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú 2Çбâ Áö¿ªÀÇ»çÁý´ãȸ : 2018-09-06 0 527 2018-08-22
482 ºÎ»ê ºÎ»ê±¤¿ª½ÃÀÇ»çȸ ¼­±¸ÀÇ»çȸ 9¿ù Çмúȸ : 2018-09-05 0 621 2018-08-22
481 ´ë±¸ 2018³â ´ëÇÑ°¨¿°ÇÐȸ ¿µ³²Áöȸ 9¿ù Áý´ãȸ : 2018-09-05 0 465 2018-08-22
480 ´ë±¸ ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ´ë±¸°æºÏÁöȸ Çмúȸ : 2018-09-04 0 690 2018-08-22
479 ¼­¿ï ¼­¿ïƯº°½Ã¸³ º¸¶ó¸Åº´¿ø ¼­³²Áö¿ª À̺ñÀÎÈÄ°ú °³¿øÀÇ Áý´ãȸ : 2018-09-04 0 648 2018-08-22
478 ÀÎõ Á¦ 3Â÷ °³¿øÀǸ¦ À§ÇÑ ´ëÇѺÎÁ¤¸ÆÇÐȸ ¿¬¼ö±³À° : 2018-09-03 0 773 2018-08-22
477 ºÎ»ê ºÎ»ê´ëÇб³º´¿ø ÇǺΰúÇÐÀÇ ÃÖ½ÅÁö°ß : 2018-09-03 0 969 2018-08-22
476 ¼­¿ï Á¦3ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ³»½Ã°æ±â±â/½ºÅÙÆ®¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-09-02 0 576 2018-08-22
475 ¼­¿ï ´ëÇÑÀ§´ëÀå³»½Ã°æÇÐȸ Á¦32ȸ Ãß°èÇмú´ëȸ : 2018-09-02 0 1,796 2018-08-22
1341 | 1342 | 1343 | 1344 | 1345 | 1346 | 1347 | 1348 | 1349 | 1350
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷